BACKGROUND: Idiopathic granulomatous mastitis (IGM) is a rare benign inflammatory disease of the breast. It is related to various etiological factors. The treatment of IGM is challenging as there is a lack of consensus in the literature and treatment options vary widely. Conservative treatment with antibiotics, glucocorticoids and immunosuppressive drugs, and surgery are used in the management of the disease. In this article we report our experience with IGM patients receiving immunosuppressive treatment. PATIENTS AND METHODS: The medical records of patients with IGM receiving systemic therapy at the Hacettepe University Hospital between October 2007 and May 2010 were reviewed. 15 cases of histopathologically proven IGM were identified. The data was examined for risk factors and success of treatment. RESULTS: 14 patients were given prednisolone together with azathioprine, and 1 patient who was pregnant at the time of diagnosis received only prednisolone (30 mg/day). 11 (73%) patients had a complete response to systemic therapy. 2 patients had a relapse, of whom 1 required surgical drainage and 1 was treated with a higher dose of glucocorticoids. CONCLUSION: Systemic therapy is a safe and effective treatment for IGM. The addition of azathioprine to glucocorticoid therapy permits quick tapering of the steroid doses and increases the treatment success.
BACKGROUND:Idiopathic granulomatous mastitis (IGM) is a rare benign inflammatory disease of the breast. It is related to various etiological factors. The treatment of IGM is challenging as there is a lack of consensus in the literature and treatment options vary widely. Conservative treatment with antibiotics, glucocorticoids and immunosuppressive drugs, and surgery are used in the management of the disease. In this article we report our experience with IGM patients receiving immunosuppressive treatment. PATIENTS AND METHODS: The medical records of patients with IGM receiving systemic therapy at the Hacettepe University Hospital between October 2007 and May 2010 were reviewed. 15 cases of histopathologically proven IGM were identified. The data was examined for risk factors and success of treatment. RESULTS: 14 patients were given prednisolone together with azathioprine, and 1 patient who was pregnant at the time of diagnosis received only prednisolone (30 mg/day). 11 (73%) patients had a complete response to systemic therapy. 2 patients had a relapse, of whom 1 required surgical drainage and 1 was treated with a higher dose of glucocorticoids. CONCLUSION: Systemic therapy is a safe and effective treatment for IGM. The addition of azathioprine to glucocorticoid therapy permits quick tapering of the steroid doses and increases the treatment success.
Authors: Dalice A Marriott; John Russell; James Grebosky; Anne Marie Wallace; Nancy Joste; Melanie E Royce Journal: Am J Clin Oncol Date: 2007-10 Impact factor: 2.339
Authors: Eric C H Lai; Wing Cheong Chan; Tony K F Ma; Alice P Y Tang; Cycles S P Poon; Heng Tat Leong Journal: Breast J Date: 2005 Nov-Dec Impact factor: 2.431
Authors: Hazel C Dobinson; Trevor P Anderson; Stephen T Chambers; Matthew P Doogue; Lois Seaward; Anja M Werno Journal: J Clin Microbiol Date: 2015-07-01 Impact factor: 5.948
Authors: Alper Akcan; A Bahadir Oz; Serap Dogan; Hülya Akgün; Muhammet Akyüz; Engin Ok; Mustafa Gök; Tutkun Talih Journal: Breast Care (Basel) Date: 2014-05 Impact factor: 2.860
Authors: Tonguç Utku Yılmaz; Bora Gürel; Sertaç Ata Güler; Mehmet Ali Baran; Büşra Erşan; Seda Duman; Zafer Utkan Journal: Eur J Breast Health Date: 2018-04-01
Authors: Rami J Yaghan; Nehad M Ayoub; Shadi Hamouri; Alia Al-Mohtaseb; Maha Gharaibeh; Lamees Yaghan; Mahmoud Al-Dari; Hiba Al-Kaff; Nabil A Al-Zoubi Journal: Int J Breast Cancer Date: 2020-01-27